CA2105888C - Utilisation d'un inhibiteur direct de la thrombine pour la fabrication d'un medicament a activite thrombolytique - Google Patents

Utilisation d'un inhibiteur direct de la thrombine pour la fabrication d'un medicament a activite thrombolytique Download PDF

Info

Publication number
CA2105888C
CA2105888C CA002105888A CA2105888A CA2105888C CA 2105888 C CA2105888 C CA 2105888C CA 002105888 A CA002105888 A CA 002105888A CA 2105888 A CA2105888 A CA 2105888A CA 2105888 C CA2105888 C CA 2105888C
Authority
CA
Canada
Prior art keywords
thrombolytic activity
phe
arg
pro
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002105888A
Other languages
English (en)
French (fr)
Other versions
CA2105888A1 (fr
Inventor
Christopher Berry
Patrice Ferrari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of CA2105888A1 publication Critical patent/CA2105888A1/fr
Application granted granted Critical
Publication of CA2105888C publication Critical patent/CA2105888C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002105888A 1992-09-11 1993-09-10 Utilisation d'un inhibiteur direct de la thrombine pour la fabrication d'un medicament a activite thrombolytique Expired - Lifetime CA2105888C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR92.10833 1992-09-11
FR9210833A FR2695562B1 (fr) 1992-09-11 1992-09-11 Utilisation d'un inhibiteur direct de la thrombine pour la fabrication d'un médicament à activité thrombolytique.

Publications (2)

Publication Number Publication Date
CA2105888A1 CA2105888A1 (fr) 1994-03-12
CA2105888C true CA2105888C (fr) 2008-04-15

Family

ID=9433400

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002105888A Expired - Lifetime CA2105888C (fr) 1992-09-11 1993-09-10 Utilisation d'un inhibiteur direct de la thrombine pour la fabrication d'un medicament a activite thrombolytique

Country Status (18)

Country Link
US (1) US5583113A (enExample)
EP (1) EP0589741B1 (enExample)
JP (1) JPH06228007A (enExample)
KR (1) KR100261526B1 (enExample)
CN (1) CN1066961C (enExample)
AT (1) ATE163856T1 (enExample)
AU (1) AU4628193A (enExample)
CA (1) CA2105888C (enExample)
CZ (1) CZ188893A3 (enExample)
DE (1) DE69317343T2 (enExample)
DK (1) DK0589741T3 (enExample)
ES (1) ES2115741T4 (enExample)
FR (1) FR2695562B1 (enExample)
IL (1) IL106981A (enExample)
NO (1) NO306537B1 (enExample)
SK (1) SK96993A3 (enExample)
TW (1) TW284691B (enExample)
ZA (1) ZA936707B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830448A (en) * 1994-06-16 1998-11-03 Genentech, Inc. Compositions and methods for the treatment of tumors
DE4421052A1 (de) 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
CZ245797A3 (cs) * 1995-02-17 1998-06-17 Basf Aktiengesellschaft Derivát amidinu dipeptidu jako inhibitor thrombinu
SA96170106A (ar) * 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
KR100689923B1 (ko) 1998-01-26 2007-03-09 애보트 게엠베하 운트 콤파니 카게 트롬빈 억제제
CN101598725B (zh) * 2009-06-23 2012-07-18 南通大学附属医院 阿加曲班在血细胞和生化常规分析中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258192A (en) * 1977-12-16 1981-03-24 Mitsubishi Chemical Industries Limited N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4318904A (en) * 1980-04-25 1982-03-09 Research Corporation Peptide affinity labels for thrombin and other trypsin-like proteases
US4929602A (en) * 1987-11-25 1990-05-29 Scripps Clinic And Research Foundation Method of inhibiting platelet dependent arterial thrombosis
US5196404B1 (en) * 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin

Also Published As

Publication number Publication date
ES2115741T3 (es) 1998-07-01
DE69317343T2 (de) 1998-10-08
IL106981A (en) 1999-03-12
ES2115741T4 (es) 2012-07-04
DK0589741T3 (da) 1998-12-21
NO933235D0 (no) 1993-09-10
SK96993A3 (en) 1994-08-10
AU4628193A (en) 1994-03-17
FR2695562B1 (fr) 1994-10-14
TW284691B (enExample) 1996-09-01
EP0589741A1 (fr) 1994-03-30
NO306537B1 (no) 1999-11-22
US5583113A (en) 1996-12-10
CZ188893A3 (en) 1994-03-16
IL106981A0 (en) 1993-12-28
JPH06228007A (ja) 1994-08-16
ZA936707B (en) 1994-03-30
NO933235L (no) 1994-03-14
DE69317343D1 (de) 1998-04-16
CN1087015A (zh) 1994-05-25
CA2105888A1 (fr) 1994-03-12
CN1066961C (zh) 2001-06-13
EP0589741B1 (fr) 1998-03-11
FR2695562A1 (fr) 1994-03-18
ATE163856T1 (de) 1998-03-15
KR100261526B1 (ko) 2000-07-15
KR940006600A (ko) 1994-04-25

Similar Documents

Publication Publication Date Title
DE69503120T3 (de) Zusammensetzungen aus einer thrombolytisch wirkende substanz und antikoagulantien, und ihre verwendungen
JP2008525468A (ja) ポストコンディショニング臓器保護作用を増強する治療補助薬
Dembińska-Kieć et al. Effect of prostacyclin on fibrinolytic activity in patients with arteriosclerosis obliterans
JP2006213736A (ja) 鎮痛剤およびその使用
CA2105888C (fr) Utilisation d'un inhibiteur direct de la thrombine pour la fabrication d'un medicament a activite thrombolytique
JP4140981B2 (ja) 再狭窄症及び動脈硬化症治療薬
Paraskevas et al. Thromboangiitis obliterans (Buerger’s disease): searching for a therapeutic strategy
US6235279B1 (en) Method for treating thromboembolic conditions by inhibiting reocclusion via the use of multiple bolus administration of thrombolytically active proteins
Sobel et al. Coronary thrombolysis with facilitated absorption of intramuscularly injected tissue-type plasminogen activator.
JPH02326B2 (enExample)
EP0106812B1 (en) Pharmaceutical composition containing a fibrinolytic agent and a diffusion factor, useful for the treatment of the myocardium infarction
KR20190072011A (ko) 나토키나제와 항염증제를 유효성분으로 포함하는 혈소판 응집 억제용 또는 혈전용해용 의약 조성물
EP1190714A2 (en) Method for the treatment of thromboembolic disorders in patients with aspirin resistance
US20250268902A1 (en) Therapeutic methods
EP0213676A2 (en) Pharmaceutical compositions containing ACTH (1-24) for the therapy of shock conditions and of respiratory and cardiocirculatory insufficiencies
EP0232697B1 (en) Pharmaceutical compositions containing acth fragments for the therapy of shock conditions and of respiratory and cardiocirculatory insufficiencies
RU2007169C1 (ru) Средство, обладающее антигипертензивным действием
US4790988A (en) Method and compositions for the treatment of thrombotic episodes
JPH09301861A (ja) ラジカル疾患用注射・点滴薬剤
WO2019211829A1 (en) Compositions and methods for treating glioblastoma
WO2001000191A2 (en) Use of fosphenytion for the treatment of acute neuropathic pain
Mizuno et al. Evaluation of manidipine hydrochloride, a new calcium antagonist, in the treatment of hypertensive patients with renal disorders
Krishna et al. Calcium channel blockers: progression of renal disease
Anderson et al. The antihypertensive profile of the angiotensin AT1 receptor antagonist, GR138950, and the influence of potential homeostatic compensatory mechanisms in renal hypertensive rats
Li et al. Inhibition of vasoconstrictor mechanisms by dazoxiben in the rat mesenteric vasculature

Legal Events

Date Code Title Description
EEER Examination request